Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 3/20 | 0.62 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.62 |
| ▸ | NPY4R | P50391 | 4/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
| ▸ | NPY2R | P49146 | 3/20 | 0.56 |
| ▸ | BACE1 | P56817 | 10/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445824 | 0.94 | NTSR2 (0.56) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL31031460 | 0.89 | NPY4R (0.54) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL29770017 | 0.88 | NTSR2 (0.68) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL29447812 | 0.88 | NTSR2 (0.69) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL30784953 | 0.88 | BACE1 (0.60) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL30445421 | 0.88 | NTSR2 (0.55) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL29611893 | 0.87 | NTSR1 (0.61) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL30471450 | 0.87 | NPY4R (0.69) | NTSR2NTSR1NPY4RNPY1RNPY2R | |
| SCHEMBL31405782 | 0.87 | BACE1 (0.55) | NTSR2NTSR1BACE1BACE2F2 | |
| SCHEMBL30462190 | 0.87 | NPY4R (0.72) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132183-A1 | T CELL RECEPTORS DIRECTED AGAINST MELANOMA-ASSOCIATED ANTIGEN AND USES THEREOF | ACAD ZIEKENHUIS LEIDEN H O D N LUMC (NL) | 2026-05-14 | — | — | US | claimed |
| US-20250367276-A1 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-12-04 | — | — | US | claimed |
| US-20250269002-A1 | CTA VACCINE CASSETTES | GRITSTONE BIO INC (US) | 2025-08-28 | — | — | US | claimed |
| EP-4565264-A2 | CTA VACCINE CASSETTES | Gritstone bio, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2024031027-A9 | CTA VACCINE CASSETTES | GRITSTONE BIO, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| EP-4536703-A1 | T CELL RECEPTORS DIRECTED AGAINST MELANOMA-ASSOCIATED ANTIGEN AND USES THEREOF | Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) | 2025-04-16 | — | — | EP | claimed |
| EP-4534554-A1 | MAGE-A1 SPECIFIC TCR AND USE THEREOF | Corregene Biotechnology Co., Ltd. (CN) | 2025-04-09 | — | — | EP | claimed |
| CN-119730873-A | Microbial analogues of tumor associated antigens and uses thereof | 国家癌症研究所IRCCS-G·帕斯卡莱基金会 | 2025-03-28 | — | — | CN | claimed |
| CN-119529098-A | Binding molecules specific for MAGE-A1 and anti-CD 3 fusion proteins | 北京可瑞生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| EP-4504343-A1 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2025-02-12 | — | — | EP | claimed |
| WO-2023239241-A1 | T CELL RECEPTORS DIRECTED AGAINST MELANOMA-ASSOCIATED ANTIGEN AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-12-14 | — | — | WO | claimed |
| WO-2023232111-A1 | MAGE-A1 SPECIFIC TCR AND USE THEREOF | 北京可瑞生物科技有限公司 | 2023-12-07 | — | — | WO | claimed |
| WO-2023194549-A1 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-10-12 | — | — | WO | claimed |
| US-20230192886-A1 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-22 | — | — | US | claimed |
| WO-2023081925-A1 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| US-20220370586-A1 | METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY | CEDARS-SINAI MEDICAL CENTER (US) | 2022-11-24 | — | — | US | claimed |
| CN-115052885-A | Specific binding molecules | 英美偌科有限公司 | 2022-09-13 | — | — | CN | claimed |
| EP-4048684-A1 | SPECIFIC BINDING MOLECULES | Immunocore Limited (GB) | 2022-08-31 | — | — | EP | claimed |
| EP-4010009-A2 | METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY | Cedars-Sinai Medical Center (US) | 2022-06-15 | — | — | EP | claimed |
| WO-2022076353-A1 | COMPOSITIONS AND METHODS FOR TREATING MAGE-A1-EXPRESSING DISEASE | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132183-A1 | T CELL RECEPTORS DIRECTED AGAINST MELANOMA-ASSOCIATED ANTIGEN AND USES THEREOF | MICA, CD74, TAP1 | NTSR2 1601/4885NTSR1 513/4885NPY4R 2181/4885 |
| US-20220370586-A1 | METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY | NFATC1, CD4, ICOS | NTSR2 3440/4885NTSR1 2814/4885NPY4R 4609/4885 |
| US-20250269002-A1 | CTA VACCINE CASSETTES | KRAS, TP53, TSG101 | NTSR2 3345/4885NTSR1 2829/4885NPY4R 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.